Ocular Therapeutix Inc (OCUL)
8.68
-0.10
(-1.14%)
USD |
NASDAQ |
Sep 27, 16:00
8.68
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Research and Development Expense (Annual): 61.06M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 61.06M |
| December 31, 2022 | 53.46M |
| December 31, 2021 | 50.08M |
| December 31, 2020 | 28.69M |
| December 31, 2019 | 41.09M |
| December 31, 2018 | 36.92M |
| Date | Value |
|---|---|
| December 31, 2017 | 30.88M |
| December 31, 2016 | 27.06M |
| December 31, 2015 | 26.61M |
| December 31, 2014 | 18.88M |
| December 31, 2013 | 10.52M |
| December 31, 2012 | 11.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
28.69M
Minimum
2020
61.06M
Maximum
2023
46.88M
Average
50.08M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Marinus Pharmaceuticals Inc | 99.39M |
| Aptevo Therapeutics Inc | 17.11M |
| Lyell Immunopharma Inc | 182.94M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |